MedTrace Logo

The Rapid Diagnosis of MCI and Depression in Patients Ages 60 and Over

NCT06011681 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 960

Last updated 2024-01-22

No results posted yet for this study

Summary

Mild cognitive impairment (MCI) leading to Alzheimer's disease and related disorders (ADRD) represents a significant health and economic burden of the rapidly expanding senior population. The accurate detection and diagnosis of MCI and its common comorbidity, late-life depression (LLD), is essential for prolonging patient quality of life and developing advancements in research and treatment options. The purpose of the proposed program is to refine Miro Health's A.I. to accurately detect, differentiate and diagnose MCI and LLD.

Conditions

Sponsors & Collaborators

  • Miro Health

    lead OTHER

Principal Investigators

  • Shenly Glenn, BS · Miro Health

Eligibility

Min Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-09-08
Primary Completion
2024-11-30
Completion
2024-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06011681 on ClinicalTrials.gov